Does targeted therapy treat chronic myeloid leukaemia?

Chronic myeloid leukaemia, or CML, begins in blood-forming cells and is linked to an abnormal signal that continually tells certain cells to multiply. Targeted medicines called tyrosine kinase inhibitors are designed to block that signal. They are usually taken regularly as tablets, and treatment is followed with blood tests and molecular monitoring. The aim is to control the leukaemia and keep the abnormal signal suppressed. The medicine may need adjustment if the response is not deep enough, side effects are troublesome, or the disease develops resistance.

Take the medicine exactly as prescribed and discuss food, antacids, supplements, and other prescriptions with your team because they may alter how it works. Keep monitoring appointments even when you feel well; CML activity can change without obvious symptoms. Tell the team about muscle cramps, swelling, weight change, diarrhoea, skin changes, breathlessness, or unusual tiredness. Never stop treatment suddenly on your own. If a dose is missed or vomiting occurs after a dose, ask what action is appropriate for your particular medicine.

Call your treatment team promptly if you develop a fever, persistent infection symptoms, marked weakness, unexpected bruising, or bleeding. Get urgent help for severe breathlessness, chest pain, fainting, new confusion, facial swelling, or a severe allergic-looking rash. These problems may not be caused by CML or its medicine, but rapid assessment helps the team protect your treatment and general health.

Which target is my medicine blocking? What result will show that I am responding? How often will molecular tests be arranged? Which side effects merit a call before my next appointment? What should I do if I miss a tablet?